Erfonrilimab
Synonyms[edit source]
Erfonrilimab, Anti-PD-L1 x CTLA-4 Bispecific Antibody KN046, Anti-PD-L1/Anti-CTLA-4 Bispecific Antibody KN046, Anti-PD-L1/CTLA-4 Bispecific Antibody KN046, ERFONRILIMAB, KN 046, KN-046, KN046
Thesaurus
A bispecific monoclonal antibody directed against both the immunosuppressive ligand, programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), and cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, erfonrilimab targets and binds to both PD-L1 expressed on tumor cells and CTLA-4 expressed on T-cells. This prevents the binding of PD-L1 to its receptor, programmed cell death protein 1 (PD-1, CD279), and inhibits the PD-1 and CTLA-4-mediated downregulation of T-cell activation and proliferation. This restores immune function and activates a sustained cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells. Both PD-L1, which is overexpressed in many human cancer cell types, and CTLA-4, an inhibitory T-cell receptor, play a role in the downregulation of the immune system and tumor evasion from host immunity. Pharmacologic Substance
- NCI Thesaurus (external)
C28227, C129822, C128036.
This concise article on Erfonrilimab incorporates public domain text from the US National Library of Medicine.
This article is a stub. You can help WikiMD by registering to expand it. |
Navigation: Wellness - Encyclopedia - Health topics - Disease Index - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.Contributors: Prab R. Tumpati, MD